RMRainer Machauer

Rainer Machauer

*This is an algorithmically generated author record based on publicly available information.

Rainer Machauer has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Discovery of NP3-742: A Structurally Diverse NLRP3 Inhibitor Identified through an Unusual Phenol Replacement

    by Juraj Velcicky, Jean-Baptiste Langlois, Michael Wright, Philipp Janser, Daniela Angst, Christelle Arnold, Karen Beltz, Silke Brenneisen, Celine Dubois, Janet Dawson, et al.

    NLRP3 is a molecular sensor present in innate immune cells which recognizes a variety of danger signals such as MSU, ATP, or Aβ. Upon activation, it seeds a protein complex termed the inflammasome, which leads to secretion of the proinflammatory cytokines IL-1β and IL-18 and initiates pyroptotic cell death. NLRP3 inflammasome activation has been associated with a wide range of diseases including atherosclerosis, gout, and cancer. In this publication, we describe the replacement of the phenol moiety with indoles in the recently described pyridazine scaffold. This replacement required a shift of the hydrogen bond donor from the “ortho” to the “meta” position, relative to the pyridazine ring. Initial indole analog 7 demonstrated a robust in vivo IL-1β inhibition, but also a significant hERG inhibition. Decreasing lipophilicity led to the discovery of NP3-742, demonstrating a favorable overall profile including diminished hERG inhibition and in vivo efficacy in a mouse peritonitis model.


  • Discovery and Optimization of Selective Inhibitors of Large Tumor Suppressor Kinases LATS1 and 2 for In Vivo Investigation of the Hippo-YAP Pathway in Tissue Regeneration

    by Kenji Namoto, Eric Vangrevelinghe, Rainer Machauer, Dirk Behnke, Nicole Buschmann, Julie Lachal, Kathrin Schipp, Mickael Sorge, Kerstin Barker, Francesca Fabbiani, et al.

    Large Tumor Suppressor kinases LATS1 and 2 (LATS1/2) are serine/threonine kinases and core regulators of the Hippo-YAP pathway. Inhibition of LATS1/2 promotes nuclear translocation of nonphosphorylated YAP, thereby initiating a downstream cascade promoting cell proliferation. We set out to investigate the potential of LATS inhibition as a therapeutic approach to enhance tissue regeneration and hereby report a structure-guided optimization of screening hit 1 for potency, binding efficiency, and physicochemical properties, leading to a highly selective, cellularly active, and orally available tool compound 7 (NIBR-LTSi) that demonstrated ex vivo target engagement and in vivo YAP target gene activation in rodents.


  • JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors

    by Edwige Lorthiois, Marc Gerspacher, Kim S. Beyer, Andrea Vaupel, Catherine Leblanc, Rowan Stringer, Andreas Weiss, Rainer Wilcken, Daniel A. Guthy, Andreas Lingel, et al.

    Rapid emergence of tumor resistance via RAS pathway reactivation has been reported from clinical studies of covalent KRASG12C inhibitors. Thus, inhibitors with broad potential for combination treatment and distinct binding modes to overcome resistance mutations may prove beneficial. JDQ443 is an investigational covalent KRASG12C inhibitor derived from structure-based drug design followed by extensive optimization of two dissimilar prototypes. JDQ443 is a stable atropisomer containing a unique 5-methylpyrazole core and a spiro-azetidine linker designed to position the electrophilic acrylamide for optimal engagement with KRASG12C C12. A substituted indazole at pyrazole position 3 results in novel interactions with the binding pocket that do not involve residue H95. JDQ443 showed PK/PD activity in vivo and dose-dependent antitumor activity in mouse xenograft models. JDQ443 is now in clinical development, with encouraging early phase data reported from an ongoing Phase Ib/II clinical trial (NCT04699188).


  • Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer’s Disease

    by Rainer Machauer, Rainer Lueoend, Konstanze Hurth, Siem J. Veenstra, Heinrich Rueeger, Markus Voegtle, Marina Tintelnot-Blomley, Jean-Michel Rondeau, Laura H. Jacobson, Grit Laue, et al.

    After identification of lead compound 6, 5-amino-1,4-oxazine BACE1 inhibitors were optimized in order to improve potency, brain penetration, and metabolic stability. Insertion of a methyl and a trifluoromethyl group at the 6-position of the 5-amino-1,4-oxazine led to 8 (NB-360), an inhibitor with a pKa of 7.1, a very low P-glycoprotein efflux ratio, and excellent pharmacological profile, enabling high central nervous system penetration and exposure. Fur color changes observed with NB-360 in efficacy studies in preclinical animal models triggered further optimization of the series. Herein, we describe the steps leading to the discovery of 3-chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide 15 (CNP520, umibecestat), an inhibitor with superior BACE1/BACE2 selectivity and pharmacokinetics. CNP520 reduced significantly Aβ levels in mice and rats in acute and chronic treatment regimens without any side effects and thus qualified for Alzheimer’s disease prevention studies in the clinic.


  • Synthesis of the Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor NB-360

    by Heinrich Rueeger, Rainer Lueoend, Rainer Machauer, Siem J. Veenstra, Philipp Holzer, Konstanze Hurth, Markus Voegtle, Mathias Frederiksen, Jean-Michel Rondeau, Marina Tintelnot-Blomley, et al.

    Starting from lead compound 4, the 1,4-oxazine headgroup was optimized to improve potency and brain penetration. Focusing at the 6-position of the 5-amino-1,4-oxazine, the insertion of a Me and a CF3 group delivered an excellent pharmacological profile with a pKa of 7.1 and a very low P-gp efflux ratio enabling high central nervous system (CNS) penetration and exposure. Various synthetic routes to access BACE1 inhibitors bearing a 5-amino-6-methyl-6-(trifluoromethyl)-1,4-oxazine headgroup were investigated. Subsequent optimization of the P3 fragment provided the highly potent N-(3-((3R,6R)-5-amino-3,6-dimethyl-6-(trifluoromethyl)-3,6-dihydro-2H-1,4-oxazin-3-yl)-4-fluorophenyl)-5-cyano-3-methylpicolinamide 54 (NB-360), able to reduce significantly Aβ levels in mice, rats, and dogs in acute and chronic treatment regimens.


  • Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors

    by Siem Jakob Veenstra, Heinrich Rueeger, Markus Voegtle, Rainer Lueoend, Philipp Holzer, Konstanze Hurth, Marina Tintelnot-Blomley, Mathias Frederiksen, Jean-Michel Rondeau, Laura Jacobson, et al.


  • Open Access

    A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice

    by Ulf Neumann, Heinrich Rueeger, Rainer Machauer, Siem Jacob Veenstra, Rainer M. Lueoend, Marina Tintelnot-Blomley, Grit Laue, Karen Beltz, Barbara Vogg, Peter Schmid, et al.

    Alzheimer’s disease (AD) is the most common form of dementia, the number of affected individuals is rising, with significant impacts for healthcare systems. Current symptomatic treatments delay, but do not halt, disease progression. Genetic evidence points to aggregation and deposition of amyloid-β (Aβ) in the brain being causal for the neurodegeneration and dementia typical of AD. Approaches to target Aβ via inhibition of γ-secretase or passive antibody therapy have not yet resulted in substantial clinical benefits. Inhibition of BACE1 (β-secretase) has proven a challenging concept, but recent BACE1inhibitors can enter the brain sufficiently well to lower Aβ. However, failures with the first clinical BACE1 inhibitors have highlighted the need to generate compounds with appropriate efficacy and safety profiles, since long treatment periods are expected to be necessary in humans. Treatment with NB-360, a potent and brain penetrable BACE-1 inhibitor can completely block the progression of Aβ deposition in the brains of APP transgenic mice, a model for amyloid pathology. We furthermore show that almost complete reduction of Aβ was achieved also in rats and in dogs, suggesting that these findings are translational across species and can be extrapolated to humans. Amyloid pathology may be an initial step in a complex pathological cascade; therefore we investigated the effect of BACE-1 inhibition on neuroinflammation, a prominent downstream feature of the disease. NB-360 stopped accumulation of activated inflammatory cells in the brains of APP transgenic mice. Upon chronic treatment of APP transgenic mice, patches of grey hairs appeared. In a rapidly developing field, the data on NB-360 broaden the chemical space and expand knowledge on the properties that are needed to make a BACE-1 inhibitor potent and safe enough for long-term use in patients. Due to its excellent brain penetration, reasonable oral doses of NB-360 were sufficient to completely block amyloid-β deposition in an APP transgenic mouse model. Data across species suggest similar treatment effects can possibly be achieved in humans. The reduced neuroinflammation upon amyloid reduction by NB-360 treatment supports the notion that targeting amyloid-β pathology can have beneficial downstream effects on the progression of Alzheimer’s disease.


  • Structure-based design and synthesis of macrocyclic peptidomimetic β-secretase (BACE-1) inhibitors

    by Rainer Machauer, Siem Veenstra, Jean-Michel Rondeau, Marina Tintelnot-Blomley, Claudia Betschart, Ulf Neumann, Paolo Paganetti


  • Macrocyclic peptidomimetic β-secretase (BACE-1) inhibitors with activity in vivo

    by Rainer Machauer, Kurt Laumen, Siem Veenstra, Jean-Michel Rondeau, Marina Tintelnot-Blomley, Claudia Betschart, Anne-Lise Jaton, Sandrine Desrayaud, Matthias Staufenbiel, Sabine Rabe, et al.